{
    "clinical_study": {
        "@rank": "36908", 
        "arm_group": {
            "arm_group_label": "Carboplatin and docetaxel", 
            "arm_group_type": "Experimental", 
            "description": "Intravenous infusion every 3 weeks Carboplatin plus docetaxel"
        }, 
        "brief_summary": {
            "textblock": "A phase II single arm study of carboplatin and docetaxel in treatment of first sensitive\n      relapse of epithelial ovarian, peritoneal or tubal cancer.\n\n      Hypothesis: Treatment with this combination in second line is safe and with a low frequency\n      of neurologic side effect."
        }, 
        "brief_title": "A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer", 
        "completion_date": {
            "#text": "December 2008", 
            "@type": "Actual"
        }, 
        "condition": "Ovarian Epithelial Cancer Recurrent", 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "detailed_description": {
            "textblock": "Evaluation of toxicity and response of treatment with carboplatin and docetaxel to patients\n      with epithelial cancer of ovary, fallopian tube or peritoneum with their first relapse\n      occurring at least 6 months after end of first line treatment- Evaluation of toxicity\n      according to Clinical Toxicity Criteria version 2."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Epithelial carcinoma of ovarian, peritoneal or fallopian tube origin.\n\n          -  Female\n\n          -  age above 18 years\n\n          -  WHO performance status 0-2\n\n          -  Life expectancy > 3 months\n\n          -  Previous treatment with one platinum and taxane containing regimen.\n\n          -  Platinum and taxane sensitive relapse\n\n          -  At least one evaluable/measurable lesion.\n\n          -  Adequate hematologic, renal and liver function\n\n          -  Consent form signed and dated before inclusion\n\n        Exclusion Criteria:\n\n          -  Prior treatment with more than one line of chemotherapy\n\n          -  Concurrent severe and/or uncontrolled co-morbid medical condition.\n\n          -  History of previous or concurrent malignancy within the previous 5 years \u2022 History of\n             prior serious allergic reactions such as anaphylactic shock\n\n          -  Pregnant or lactating women (or potentially fertile women not using adequate\n             contraception)\n\n          -  Peripheral neuropathy > Grade 2\n\n          -  History of allergy to drugs containing the excipient TWEEN 80\u00ae.\n\n          -  Concomitant administration of any other experimental drug under investigation or\n             concurrent treatment with any other anti-cancer therapy\n\n          -  Clinical evidence of brain metastases"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02026921", 
            "org_study_id": "NSGO-OC-0303"
        }, 
        "intervention": [
            {
                "arm_group_label": "Carboplatin and docetaxel", 
                "description": "Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": "Carboplatin"
            }, 
            {
                "arm_group_label": "Carboplatin and docetaxel", 
                "description": "75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase II study,", 
            "Recurrent platinum-sensitive ovarian cancer", 
            "docetaxel", 
            "Carboplatin", 
            "Toxicity"
        ], 
        "lastchanged_date": "December 31, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aalborg", 
                        "country": "Denmark", 
                        "zip": "9000"
                    }, 
                    "name": "Aalborg University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "2730"
                    }, 
                    "name": "Herlev University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampere", 
                        "country": "Finland"
                    }, 
                    "name": "Tampere University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "0310"
                    }, 
                    "name": "Norwegian Radium Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Denmark", 
                "Finland", 
                "Norway"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Docetaxel and Carboplatin as Second Line Chemotherapy in First Relapse of Platinum Sensitive Epithelial Ovarian Cancer", 
        "overall_official": {
            "affiliation": "NSGO-CTU", 
            "last_name": "Gunnar B Kristensen, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Norway: Norwegian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Safety will be established by grading the observed toxicities using the NCI Common Toxicity Criteria (CTC Version 2.0). All toxicities observed within 30 dayes of last chemocourse will be included.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 30 days after last chemotherapy course"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02026921"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response rate according to Resist 1.0 Response rate is the proportion of patients that achieve CR or PR.", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 dayes after last chemotherapy course"
            }, 
            {
                "description": "Time from start of treatment to the earlier date of assessment of progression or death by any cause.", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 year"
            }
        ], 
        "source": "Nordic Society for Gynaecologic Oncology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nordic Society for Gynaecologic Oncology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2004", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}